The relationship between the regional abdominal adipose tissue distribution and the serum uric acid levels in people with type 2 diabetes mellitus

A total of 699 people with type 2 DM and who had undergone abdominal computed tomography assessment of the visceral fat area and subcutaneous fat area were included. The serum uric acid levels were measured by the uricase method. Hyperuricemia was defined by cut-off value of > 7 mg/dl for men and > 6 mg/dl for women.The visceral fat area was positively associated with the serum uric acid levels after adjustment for age, sex, systolic blood pressure, diastolic blood pressure, serum creatinine, hemoglobin, serum albumin, serum high-density lipoprotein, serum triglyceride and hemoglobin A1c (β-coefficient = 0.117, p < 0.001). The logistic regression analysis showed that the visceral fat area was the significant independent predictor of hyperuricemia (OR 2.33, 95% CI, 1.21-4.50, p = 0.012). But there was no significant association between the subcutaneous fat area and the serum uric acid levels (β-coefficient = 0.061, p = 0.255).our data shows that the visceral fat area was positively associated with the serum uric acid levels, but the subcutaneous fat area was not in people with type 2 DM.Hyperuricemia or elevated serum uric acid levels have been considered not only an independent risk factor for cardiovascular diseases but this also plays a role in the development of metabolic diseases [1-4]. Previous studies reported that the serum uric acid level is associated with the individual components of metabolic syndrome such as obesity, dyslipidemia and hypertension [5,6]. As for the association between the serum uric acid levels and obesity, a number of epidemiological and clinical studies have demonstrated a positive correlation between the serum uric acid levels and obesity [5,7].The visceral fat component and the subcutaneous fat component may have differential metabolic risks [8]. The visceral fat component is metabolically active and it regulates numerous adipocytokines and other vasoactive substances, which may be associated with an increased cardiometabolic risk [9-